Abstract
Studies of hepatitis C virus (HCV) infection amongst injecting drug users (IDUs) have suggested that this population can be separated into two risk groups (naive and experienced) with different injecting risk behaviours. Understanding the differences between these two groups and how they interact could lead to a better allocation of prevention measures designed to reduce the burden of HCV in this population. In this paper we develop a deterministic, compartmental mathematical model for the spread of HCV in an IDU population that has been separated into two groups (naive and experienced) by time since onset of injection. We will first describe the model. After deriving the system of governing equations, we will examine the basic reproductive number \(R_0\), the existence and uniqueness of equilibrium solutions and the global stability of the disease free equilibrium (DFE) solution. The model behaviour is determined by the basic reproductive number, with \(R_0=1\) a critical threshold for endemic HCV prevalence. We will show that when \(R_0\le 1\), and HCV is initially present in the population, the system will tend towards the globally asymptotically stable DFE where HCV has been eliminated from the population. We also show that when \(R_0>1\) there exists a unique non-zero equilibrium solution. Then we estimate the value of \(R_0\) from epidemiological data for Glasgow and verify our theoretical results using simulations with realistic parameter values. The numerical results suggest that if \(R_0>1\) and the disease is initially present then the system will tend to the unique endemic equilibrium.
Similar content being viewed by others
References
Advisory Council on the Misuse of Drugs (2009) The primary prevention of Hepatitis C among injecting drug users. http://drugs.homeoffice.gov.uk/publication-search/acmd/acmdhepcreport22835.pdf (accessed 2010)
Aitken CK, Lewis J, Tracy SL, Spelman T, Bharadwaj M, Bowden DS, Drummer H, Hellard ME (2008) High incidence of Hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48:1749–1752
Cassin S, Geoghegan T, Cox G (1998) Young injectors: a comparative analysis of risk behaviour. Ir J Med Sci 167:234–237
Corson S, Greenhalgh D, Hutchinson S (2011) Mathematically modelling the spread of hepatitis C in injecting drug users. Math Med Biol. doi:10.1093/imammb/dqr011
Corson S, Greenhalgh D, Palmateer N, Weir A, Hutchinson S (2011) Risk of hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: a systematic review. Int J Drug Policy 22:102–108
Diekmann O, Heesterbeek JAP (2000) Mathematical epidemology of infectious diseases: model building, analysis and interpretation. Wiley series in mathematical and computational biology. Wiley, Sussex
Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N, Purcell RH (1992) Lack of protective immunity against reinfection with hepatitis C virus. Science 258:135–140
Frischer M, Leyland A, Cormack R, Goldberg DJ, Bloor M, Green ST, Taylor A, Covell R, McKeganey N, Platt S (1993) Estimating the population prevalence of injection drug use and infection with human immunodeficiency virus among injection drug users in Glasgow, Scotland. Am J Epidemiol 138: 170–181
Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D (1998) Prevalence and incidence of Hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr 18:S11–S19
Gatica JA, Smith HL (1977) Fixed point techniques in a cone with applications. J Math Anal Appl 61:58–71
Greenhalgh D (1993) Existence, threshold and stability results for an age-structured epidemic model with vaccination and non separable transmission coefficient. Int J Syst Sci 24:641–668
Greenhalgh D (1997) Bounds on endemic disease levels, risks and basic reproductive numbers in heterogeneous models for HIV/AIDS amongst injecting drug users. J Biol Syst 5:151–180
Gruer L, Cameron J, Elliot L (1993) Building a city wide service for exchanging needles and syringes. Br Med J 306:1394–1397
Hagan H, des Jarlais D (2000) HIV and HCV infection among injecting drug users. Mt Sinai J Med 67: 423–428
Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR (2002) Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 186:1558–1564
Hope VD, Judd A, Hickman M, Lamagni T, Hunter G, Stimson GV, Jones S, Donovan L, Parry JV, Gill ON (2001) Prevalence of Hepatitis C among injection drug users in England and Wales: is harm reduction working? Am J Public Health 91:38–42
HPS (1990–1993) Health protection Scotland survey of Glasgow IDUs during 1990–1993. Health Protection Scotland, Glasgow
HPS (2008–2009) Health Protection Scotland survey of Glasgow IDUs in 2008–2009. Health Protection Scotland, Glasgow
Hutchinson S, Bird S, Taylor A, Goldberg D (2006) Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: implications for prevention. Int J Drug Policy 17:211–221
Hutchinson S, Taylor A, Goldberg D, Gruer L (2000) Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990 to 1994: Implications for control and prevention of blood-borne viruses. Addiction 95:931–940
Judd A, Hutchinson S, Wadd S, Hickman M, Taylor A, Jones S, Parry J, Cameron S, Rhodes T, Ahmed S, Bird S, Fox R, Renton A, Stimson G, Goldberg D (2005) Prevalence of, and risk factors for, Hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepat 12:655–662
Kapadia F, Vlahov D, des Jarlais DC, Strathdee SA, Ouellet L, Morse EVE, Williams I, Garfein RS, Second Collaborative Injection Drug User Study (CIDUS-II) Group (2002) Does bleach disinfection of syringes protect against Hepatitis C infection among young adult injection drug users? Epidemiology 13:738–741
Kaplan EH, O’Keefe E (1993) Let the needles do the talking! Evaluating the New Haven needle exchange. Interfaces 23:7–26
Kretzschmar M, Wiessing L (2004) Modelling the transmission of Hepatitis C in injecting drug users. In: Jager J, Limburg W, Kretzschmar M, Postma M, Wiessing L (eds) Hepatitis C and injecting drug use: impact, costs and policy options. European Monitoring Centre for Drugs and Drug Addiction, Lisbon, pp 143–159
Kreyszig E (1989) Introductory functional analysis with applications. Wiley, USA
Lajmanovich A, Yorke JA (1976) A deterministic model for Gonorrhea in a non-homogeneous population. Math Biosci 28:221–236
Macey R, Oster G, Zahnley T (2000) Berkeley Madonna, UC Berkeley, USA. http://www.berkeleymadonna.com (accessed 2008)
Mathei C, van Dooreen S, Lemey P, van Damme P, Buntinx F, Vandamme A-M (2008) The epidemic history of hepatitis C among injecting drug users in Flanders. Belgium J Viral Hepat 15:399–408
Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Valhov D, Thomas DL (2011) Changes in blood-borne infection risk among injection drug users. J Infect Dis 203:587–594
Mehta SH, Cox A, Hoovere DR, Wang X, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas D (2002) Protection against persistence of Hepatitis C. Lancet 359:1478–1483
Meyer CD (2000) Matrix analysis and applied linear algebra. SIAM, Philadelphia
Micallef JM, Kaldor JM, Dore GJ (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13:34–41
Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I (2007) High incidence of hepatitis C virus infection within a cohort of injecting drug users. J Viral Hepat 14:413–418
National Treatment Agency (2009) Does syringe cleaning work? http://www.harmreductionworks.org.uk/2_films/does_cleaning_syringes_work.html (accessed 2010)
NESI (2010) The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV and injecting risk behaviours among injecting drug users attending needle exchanges in Scotland, 2008/2009. Technical report, University of the West of Scotland and Health Protection Scotland and West of Scotland Specialist Virology Centre, Paisley
Oden JT, Demkowicz LF (1996) Applied functional analysis: a first course for students of mechanics and engineering science (civil engineering and engineering mechanics series). CRC Press, Florida
Paintsil E, He H, Peters C, Lindenbach BD, Heimer R (2010) Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis 202:984–990
Roy E, Alary M, Morissette C, Leclerc P, Boudreau J-F, Parent R, Rochefort J, Caessens C, Group TSW (2007) High Hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J Sex Trans Dis AIDS 18:23–27
Roy E, Boudreau J-F, Boivin JF (2009) Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend 102:158–161
Scottish Executive (2008) Hepatitis C action plan for Scotland, Edinburgh. http://www.scotland.gov.uk/Resource/Doc/222750/0059978.pdf (accessed 2011)
Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558–567
Sutton AJ, Gray NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M (2006) Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis 6:1–10
Taylor A, Goldberg D, Hutchinson S, Cameron S, Fox R (2001) High risk injecting behaviour among injectors from Glasgow: cross sectional community wide surveys 1990–1999. J Epidemiol Community Health 55:766–767
Taylor A, Goldberg D, Hutchinson S, Cameron S, Gore SM, McMenamin J, Green S, Pithie A, Fox R (2000) Prevalence of Hepatitis C virus infection among injecting drug users in Glasgow 1990–1996: are current harm reduction strategies working? J Infect 40:176–183
Van Beek I, Buckley R, Stewart M, MacDonald M, Kaldor J (1994) Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourin Med 70:321–324
Vickerman P, Hickman M, Judd A (2007) Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol 36:396–405
Vickerman P, Platt L, Hawkes S (2009) Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan. Sex Transm Infect 85:23–30
World Health Organisation (2000) Hepatitis C Fact Sheet 164. World Health Organisation, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed 2009)
Acknowledgments
We would like to thank Health Protection Scotland, the Engineering and Physical Sciences Research Council and the University of Strathclyde for funding this research, as well as Health Protection Scotland and the University of West of Scotland for the provision of survey data on IDUs.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
1.1 A: Derivation of \(\varLambda _{jk}\) terms
Let \(\lambda _j\) denote the rate at which IDUs in experience group \(j\) share needles and syringes, \(n_j\) denote the number of IDUs in experience group \(j\) and \(s_{jk}\) denote the fraction of shared injections that an IDU in experience group \(j\) will perform while using a needle and syringe which was last used by an IDU in experience group \(k\). Then
denotes the total number of shared injections in a time interval of length \(\varDelta t\) made by the entire set of IDUs in experience group \(j\) with needle and syringes that were last used by IDUs in experience group \(k\). Since there are \(m_k\) of these needles and syringes in total, the total rate at which an IDU in experience group \(j\) picks up a single one of these needles and syringes is given by
1.2 B: Constraint on \(s_{01}\) and \(s_{10}\)
Define \(m_0\,(m_1)\) to be the number of naive (experienced) needles and syringes in circulation (as discussed in Sect. 3). Ignoring the infection status of the needles and syringes we obtain the following equations
where \(\varLambda _{jk}=\dfrac{\lambda _j s_{jk}n_j}{m_k}\), \(j,k=0,1\), denotes the rate at which an IDU in group \(j\) picks up a needle and syringe last used by a group \(k\) IDU and \(n_0\) and \(n_1\) are, respectively, the number of naive and experienced IDUs at time t. The above equations imply that at equilibrium
which implies that
Note that \(n_0+n_1=n\), the constant number of IDUs in the population and
Hence as \(t\rightarrow \infty \), \(n_0\rightarrow \mu n/(\mu +\eta )\) and \(n_1\rightarrow \eta n/(\mu +\eta )\) so this constraint becomes
If this condition is not satisfied then Eqs. (53) and (54) imply that one of \(m_0, m_1\) eventually becomes negative. If condition (57) is satisfied then from (56) we have
Integrating over \([0, t]\) gives
which implies that
where \(n_{0}^*=\mu n/(\mu +\eta )\). Using Eq. (56) and the fact that \(n_1=n-n_0\) we can use a similar argument to that used above to obtain
where \(n_{1}^*=\eta n/(\mu +\eta )\). Substituting (58) and (59) into Eq. (53) we find that
Integrating over \([0, t]\) we have
Similarly
Hence, as \(t\rightarrow \infty \), \(m_0(t)\) monotonically tends to
Similarly \(m_1(t)\) monotonically tends to
So provided that both (60) and (61) are positive then \(m_0(t)\) and \(m_1(t)\) will approach strictly positive values. Furthermore, if the spread of HCV has been going on for a long period of time before the model is started we can expect that
In this case we see from (60) and (61) that the number of needles and syringes in group will not change much from their initial values.
1.3 C: Derivation of \(\psi _0\) and \(\psi _1\)
At time \(t\), the total rate at which needles and syringes in the naive group are used is given by
where \(n_0\) and \(n_1\) are, respectively, the number of naive and experienced IDUs. Also the total rate at which needles and syringes in this group are used or exchanged is given by
Hence the probability of choosing an unexchanged needle and syringe from the needles and syringes in the naive group is given by
Similarly
1.4 D: Derivation of K = \(\mathbf M \)(K)K
Substituting the equilibrium expressions for \(\pi _y^{0*}\), \(\pi _y^{1*}\), \(\pi _h^{0*}\) and \(\pi _h^{1*}\) given by (20), (24) and (26) into
we obtain
Here \(M_{00}({\varvec{K}}^*)\) is the first term in the large square brackets multiplying \(K_0^*, M_{01}({\varvec{K}}^*)\) is the second term in the large square brackets multiplying \(K_1^*\), and \({\varvec{K}}^*=({\varvec{K}}_1^*, {\varvec{K}}_2^*)\). Similarly
Similarly to the above \(M_{10} ({\varvec{K}}^*)\) is the first term in the large square brackets multiplying \(K_0^*\) and \(M_{11}({\varvec{K}}^*)\) is the second term in the large square brackets multiplying \(K_1^*\).
Hence, it is possible to write this system in the form
If we examine the \(M_{00}({\varvec{K}}^*)\), \(M_{01}({\varvec{K}}^*), M_{10}({\varvec{K}}^*)\) and \(M_{11}({\varvec{K}}^*)\) terms more closely we can see that each term is greater than or equal to zero and strictly decreasing in \(K_0^*\) and \(K_1^*\). In addition, we see that
where
and
Rights and permissions
About this article
Cite this article
Corson, S., Greenhalgh, D. & Hutchinson, S.J. A time since onset of injection model for hepatitis C spread amongst injecting drug users. J. Math. Biol. 66, 935–978 (2013). https://doi.org/10.1007/s00285-012-0577-y
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00285-012-0577-y
Keywords
- Hepatitis C
- Injecting drug users
- Basic reproductive number
- HCV
- Time since onset of injection
- Mathematical model